CAR-T cell therapy vs bispecific antibodies for pediatric relapsed B-ALL after second relapse: sequencing and selection?

6F with B-cell ALL, initial diagnosis at age 3. Achieved CR1 on COG AALL0434. First relapse at 18 months off therapy (late marrow relapse). Achieved CR2 with FLAG-IDA, underwent allogeneic HSCT from matched sibling donor. Now, 14 months post-transplant, she has second relapse (marrow blasts 34%, MRD positive by flow cytometry).

Molecular: CD19+, CD22+, no KMT2A rearrangement, Ph-negative. No prior immunotherapy exposure.

The decision:

Tisagenlecleucel (CAR-T): FDA-approved for pediatric relapsed B-ALL. CR rate 81% in ELIANA trial. But manufacturing takes 3-4 weeks, and she has >30% blasts.
Blinatumomab (bispecific): FDA-approved. CR rate 39% in relapsed/refractory B-ALL (Tower trial). Available immediately.
Inotuzumab ozogamicin: CR rate 81% in INO-VATE trial, but almost exclusively adult data. Risk of VOD, especially post-transplant.

Questions:

Do you bridge with blinatumomab to reduce blast burden, then proceed to CAR-T?
Or do you use blinatumomab as definitive therapy and reserve CAR-T for potential third relapse?
How do you manage the waiting period for CAR-T manufacturing in a child with 34% marrow blasts?

This is one of the most consequential decisions in pediatric oncology. At Royal Marsden, we have treated 23 pediatric r/r B-ALL patients with CAR-T (tisagenlecleucel) and 15 with blinatumomab. Here is my approach for this case:

My recommendation: Bridge with blinatumomab, then definitive CAR-T.

Rationale for this sequencing:

Blast burden matters for CAR-T: The ELIANA subgroup analysis showed that patients with < 5% blasts at time of CAR-T infusion had significantly better CR rates (91%) and longer remission duration compared to those with > 50% blasts (72% CR). Debulking before CAR-T improves outcomes.
Blinatumomab as bridge: Start blinatumomab immediately (no manufacturing delay). Cycle 1: 5 mcg/m2/day continuous IV for days 1-7, then 15 mcg/m2/day for days 8-28. Our pediatric experience: 60% of patients achieve blast reduction to < 5% after 1 cycle, which is sufficient for CAR-T eligibility.
Timing: During the blinatumomab bridging cycle (4 weeks), simultaneously initiate the CAR-T manufacturing process (leukapheresis on day 1, before starting blinatumomab). Manufacturing takes 22-28 days. The timelines align.

Why NOT blinatumomab as definitive therapy:

39% CR rate (Tower) is inadequate for a child with curative intent
Even among responders, relapse rate is high (65% at 18 months)
CAR-T provides a fundamentally different mechanism: persistent T-cell surveillance
ELIANA 3-year EFS was 44%, which is the best available for third-line therapy

Managing the waiting period:

Blinatumomab bridge (as above)
If blinatumomab fails to reduce blasts: low-dose cyclophosphamide + vincristine (mini-CVP) as alternative debulking
Close MRD monitoring during bridge
Ensure adequate organ function for CAR-T (especially cardiac, per institutional protocols)

Critical consideration: This child already had an allo-HSCT. Post-transplant CAR-T is feasible but carries higher CRS risk. We pre-medicate with dexamethasone and have tocilizumab on standby from infusion day 0.

Dr. Mitchell's protocol aligns with our evolving approach at Tata Memorial. We have treated 8 post-transplant relapsed B-ALL patients in the past 2 years. Sharing our experience:

Our outcomes with the blinatumomab-bridge-to-CAR-T approach (n=5):

4/5 achieved blast reduction < 5% on blinatumomab
All 4 proceeded to tisagenlecleucel
3/4 achieved CR after CAR-T (1 had CD19-negative relapse at 6 months)
CRS: Grade 2 in 2 patients, Grade 3 in 1 (managed with tocilizumab)

The Indian context adds a unique challenge: CAR-T manufacturing is done overseas for most of our patients (Novartis site in New Jersey). The logistics add 2-3 weeks to the timeline. We are now partnering with IIT Bombay on a domestically manufactured CD19 CAR-T product that should reduce turnaround to 14 days.

One point of disagreement with Dr. Mitchell: I am less concerned about the blast burden threshold for CAR-T. In our experience, patients with 15-30% blasts at time of infusion had comparable CR rates to those with < 5%, though CRS severity was higher. If blinatumomab fails as a bridge, I would still proceed to CAR-T rather than delaying further with cytotoxic chemotherapy.

On inotuzumab: We used it in 3 pediatric cases. 2/3 achieved CR, but 1 developed severe VOD (grade 4, required defibrotide). In a post-transplant patient (already at elevated VOD risk), I would avoid inotuzumab for this case.

2 Answers